Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with tirzepatide
image: The only peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software.
Credit: Mary Ann Liebert, Inc.
In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular disease (CVD) and diabetic kidney disease (DKD) in overweight and obese (OW/OB) adults with Type 1 Diabetes treated with tirzepatide, a dual-incretin approved for use in individuals with type 2 diabetes associated with CVD and DKD. Click here to read the article now.
Satish Garg, MD, from the University of Colorado Denver and Editor-in-Chief of Diabetes Technology & Therapeutics, and coauthors, analyzed data for the off-label long-term (21 months) use of tirzepatide in 84 OW/OB adults with type 1 diabetes.
Patients using tirzepatide lost significantly more weight compared to a gain of weight in controls. The HbA1c decreased more in patients using tirzepatide than in controls. Patients using tirzepatide significantly improved total and LDL cholesterol, systolic blood pressure, and eGFR, a measure of kidney function. To the best of our knowledge this is the first study that shows improvement in cardiorenal biomarkers in OW/OB subjects with T1D treated for 21 months with tirzepatide, according to the investigators.
“We strongly recommend a long-term randomized control trial with tirzepatide in patients with type 1 diabetes,” concluded the investigators.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.